| Budget Amount *help |
¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Outline of Final Research Achievements |
The purpose of this study was to develop a "Subjective Cognitive Rating Scale: SCRS" of breast cancer patients receiving hormonal therapy, and to clarify the actual subjective cognitive decline in breast cancer patients.
A scale draft was created along the steps of the scale development. A reliability and validity study in patients was conducted and 402 subjects were analyzed. As a result, the scale's internal consistency and construction validity were confirmed.The subjects were divided into three groups by SCRS score: a ”high score group,” a ”middle score group,” a ”low score group.” In the high score group, the mean scores of symptoms, such as menopausal symptoms, fatigue, depression and anxiety were significantly higher. In addition, in the high score group, patients' QOL was decreased, and the actual condition of the patient's cognitive problems affecting their social life was revealed.
|
